Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

2nd May 2025 14:15

RNS Number : 2926H
Haleon PLC
02 May 2025
 

 

Haleon plc: Director/PDMR Shareholding 

 

​2 May 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").

 

On 2 May 2025, the Company received notification of the following transaction as detailed below.

 

 

 

Details of the person discharging managerial responsibilities / person closely associated  

 

a)

 

Name

 

Asmita Dubey

 

 

Reason for the notification  

 

a)

 

Position/status

 

 

Independent Non-Executive Director - PDMR

b)

 

Initial notification /Amendment

 

Initial Notification 

 

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  

 

a)

 

Name

 

Haleon plc 

b)

 

LEI

 

549300PSB3WWEODCUP19 

 

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

Identification code

GB00BMX86B70

 

b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares in the Company  

c)

 

Price(s) and volume(s)

Price(s) 

Volume(s) 

£4.01

15,424

d)

 

Aggregated information

 N/A - single transaction

- Aggregated volume 

- Price 

e)

 

Date of the transaction

 

2 May 2025

f)

 

Place of the transaction

 

London Stock Exchange (XLON)

 

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBDGDUDUGDGUD

Related Shares:

Haleon
FTSE 100 Latest
Value8,684.56
Change50.81